Waters Corporation Files Second Quarter 10-Q With SEC
The analytical instruments maker submitted its quarterly report as insider Christopher Kuebler executed stock options.
Quarterly Disclosure Filed
Waters Corporation, the Massachusetts-based analytical instruments manufacturer with a market capitalization of approximately $40 billion, filed its quarterly 10-Q report with the Securities and Exchange Commission on August 11, 2026. The regulatory filing provides investors with the company's financial performance and operational updates for the second quarter of 2026.
The stock closed at $411.77 ahead of the filing, reflecting the company's position as a major player in the life sciences and laboratory equipment sector.
Recent Insider Activity
Concurrent with the quarterly filing period, the company has seen notable insider transactions. Christopher A. Kuebler, a company insider, exercised stock options twice for 3,626 shares each and subsequently sold 3,626 shares, according to MarginX data. Such options exercises and sales are common among executives as part of compensation plans, though the timing alongside the quarterly filing may draw investor attention.
Looking Ahead
Waters Corporation is expected to report its third quarter 2026 results on November 3, 2026, according to MarginX data. This timeline places the earnings release shortly after the Federal Open Market Committee's October 28 rate decision, potentially influencing market reception of the company's performance.
The broader macroeconomic backdrop will feature several key Federal Reserve decisions in the coming months, with FOMC meetings scheduled for September 16 (with projections), October 28, and December 9 (with projections). These monetary policy decisions could impact capital equipment spending patterns across Waters' customer base in pharmaceutical, biotechnology, and academic research institutions.
As a supplier of high-precision analytical instruments, Waters' performance often correlates with research and development spending levels in the pharmaceutical and life sciences sectors, areas that can be sensitive to both interest rate environments and broader economic conditions.
The 10-Q filing represents standard quarterly disclosure requirements for publicly traded companies and provides detailed financial statements, management discussion and analysis, and risk factor updates.
This article was generated by MarginX from public news on 2026-08-11. It is not investment advice.